MelhemMSolhMD

PubMed

• Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant.
  Michael T Aubrey, Katelin C Jackson, Xu Zhang, Christina L Roark, H Kent Holland, Scott R Solomon, Lizamarie Bachier-Rodriguez, Melhem M Solh, Lawrence E Morris, Asad ...> ;Transplantation and Cellular Therapy. 2024 Mar 30
• Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
  Xu Zhang, H Kent Holland, Lizamarie Bachier-Rdriguez, Lawrence E Morris, Scott R Solomon, Melhem Solh, Asad Bashey> ;Transplantation and Cellular Therapy. 2024 Mar 27
• 1 citations
  Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of.
  Mark J Levis, Mehdi Hamadani, Brent Logan, Richard J Jones, Anurag K Singh, Mark Litzow, John R Wingard, Esperanza B Papadopoulos, Alexander E Perl, Robert J Soiffer, ...> ;Journal of Clinical Oncology. 2024 Mar 12
• Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation.
  Saffiya Z Bashey, Scott R Solomon, Xu Zhang, Lawrence E Morris, H Kent Holland, Lizamarie Bachier, Melhem M Solh> ;Bone Marrow Transplantation. 2024 Apr 1
• 1 citations
  Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.
  Hamadani, M., Spira, A., Zhou, X., Liao, L., Chen, L., Radford, J., Ai, W., Solh, M., Ardeshna, K., Hess, B., Caimi, P., Stathis, A., Carlo-Stella, C., Alderuccio, J.,...> ;Blood Advances. 2024 Jan 9
• PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
  Alderuccio, J., Reis, I., Hamadani, M., Nachiappan, M., Leslom, S., Kahl, B., Ai, W., Radford, J., Solh, M., Ardeshna, K., Hess, B., Lunning, M., Zinzani, P., Stathis,...> ;Clinical Cancer Research. 2024 Jan 5
• Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
  Abid, M. B., Hemant S Murthy, Mei-Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly, Ankit Kansagra, Fotios V Michelis, Taiga Nishihori, Mrinal Pat...> ;Blood Advances. 2023 Nov 28
• 11 citations
  Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
  Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H Tomasson, Michael A Damore, Sibo Jiang, Cynthia Basu, A...> ;Nature Medicine. 2023 Oct 1
• 5 citations
  Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
  Paolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, Kirit M Ardeshna, Mehdi Hamadani, Brian Hess, Brad S Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi...> ;Haematologica. 2024 Apr 1
• 3 citations
  Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant.
  Scott R Solomon, Melhem Solh, Lawrence E Morris, H Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Caitlin Guzowski, Katelin C Jackson, Stacey Brown, Asad Bashey> ;Blood Advances. 2023 Sep 26
• 48 citations
  Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
  Javier Bolaños-Meade, Mehdi Hamadani, Juan Wu, Monzr M Al Malki, Michael J Martens, Lyndsey Runaas, Hany Elmariah, Andrew R Rezvani, Mahasweta Gooptu, Karilyn T Larkin...> ;The New England Journal of Medicine. 2023 Jun 22
• 2 citations
  A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.
  Roni Tamari, Donal P McLornan, Kwang Woo Ahn, Noel Estrada-Merly, Juan Carlos Hernández-Boluda, Sergio Giralt, Jeanne Palmer, Robert Peter Gale, Zachariah DeFilipp, Da...> ;Blood Advances. 2023 Aug 8
• 2 citations
  Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
  Naresh Bumma, Binod Dhakal, Raphael Fraser, Noel Estrada-Merly, Kenneth Anderson, César O Freytes, Gerhard C Hildebrandt, Leona Holmberg, Maxwell M Krem, Cindy Lee, La...> ;Cancer. 2023 Jul 15
• 3 citations
  Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors.
  Asad Bashey, Xu Zhang, Lawrence E Morris, H K Holland, Lizamarie Bachier-Rodriguez, Scott R Solomon, Melhem Solh> ;Blood Advances. 2023 Aug 8
• Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients.
  Michael Boyiadzis, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M Badawy, Minoo Battiwalla, Ne...> ;Leukemia. 2023 May 1
• 11 citations
  Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
  Brittany Knick Ragon, Mithun Vinod Shah, Anita D'Souza, Noel Estrada-Merly, Lohith Gowda, Gemlyn George, Marcos de Lima, Shahrukh Hashmi, Mohamed A Kharfan-Dabaja, Nav...> ;Blood Advances. 2023 Jun 27
• 10 citations
  Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
  Guru Subramanian Guru Murthy, Soyoung Kim, Noel Estrada-Merly, Muhammad Bilal Abid, Mahmoud Aljurf, Amer Assal, Talha Badar, Sherif M Badawy, Karen Ballen, Amer Beitin...> ;Haematologica. 2023 Jul 1
• 9 citations
  The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Tra...
  Matthew Mei, Raju Pillai, Soyoung Kim, Noel Estrada-Merly, Michelle Afkhami, Lixin Yang, Zhuo Meng, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Amer Beitinjane...> ;Haematologica. 2023 Jan 1
• 6 citations
  Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular T...
  Zachariah DeFilipp, Stefan O Ciurea, Corey Cutler, Marie Robin, Erica D Warlick, Ryotaro Nakamura, Andrew M Brunner, Bhagirathbhai Dholaria, Alison R Walker, Nicolaus ...> ;Transplantation and Cellular Therapy. 2023 Feb 1
• 1 citations
  Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD).
  Melhem M Solh, Chloe Farnham, Scott R Solomon, Asad Bashey, Lawrence E Morris, H Kent Holland, Xu Zhang> ;Bone Marrow Transplantation. 2023 Feb 1
• 1 citations
  Graft-Versus-Host Disease (GVHD) after Post-Transplant Cyclophosphamide or Conventional GVHD Prophylaxis: Same Title, Different Song.
  Melhem Solh> ;Transplantation and Cellular Therapy. 2022 Oct 1
• 16 citations
  Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase ...
  Amy E DeZern, Mary Eapen, Juan Wu, Julie-An Talano, Melhem Solh, Blachy J Dávila Saldaña, Chatchada Karanes, Mitchell E Horwitz, Kanwaldeep Mallhi, Sally Arai, Nosha F...> ;The Lancet. Haematology. 2022 Sep 1
• Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
  Juan P Alderuccio, Weiyun Z Ai, John Radford, Melhem Solh, Kirit M Ardeshna, Matthew A Lunning, Brian T Hess, Pier L Zinzani, Anastasios Stathis, Carmelo Carlo-Stella,...> ;Blood Advances. 2022 Aug 23
• 3 citations
  High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
  Scott R Solomon, Stacey Brown, Nancy Shegda, Katelin C Jackson, Xu Zhang, Asad Bashey, H Kent Holland, Lawrence E Morris, Melhem Solh> ;Transplantation and Cellular Therapy. 2022 Aug 1
• 2 citations
  Lineage-Specific Relapse Prediction After Haploidentical Transplantation With Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group...
  Scott R Solomon, Michael T Aubrey, Xu Zhang, Katelin C Jackson, Christina L Roark, Brian M Freed, Lawrence E Morris, H Kent Holland, Melhem M Solh, Asad Bashey> ;Transplantation and Cellular Therapy. 2022 Sep 1
• Join now to see all

Abstracts/Posters

• Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Trans...
  Melhem Solh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Mor... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Inciden... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hemato... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• The Choice of Induction Regimen Affects Post Remission Survival of Acute Myelogenous Leukemia (AML) Patients with Intermediate or Poor Risk Disease 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all